Key Takeaways
Inovio's partner in China, ApolloBio, announced positive topline results from a pivotal Phase 3 trial of its DNA immunotherapy VGX-3100 for treating cervical dysplasia, a precancerous condition caused by HPV.
"We believe these positive topline results for VGX-3100 reflect both the potential of our DNA medicine platform in HPV-related diseases and the power of partnerships to advance innovative DNA immunotherapies," said Dr. Jacqueline Shea, Inovio's President and Chief Executive Officer.
The trial successfully met its primary composite endpoint, demonstrating both histopathologic regression of high-grade lesions and clearance of the underlying HPV-16 or HPV-18 infection. These two high-risk HPV types are responsible for approximately 70 percent of cervical cancer cases worldwide. The study, led by the Cancer Hospital, Chinese Academy of Medical Sciences, observed a favorable safety profile with no new significant risks.
The positive data paves the way for ApolloBio to seek regulatory approval in China, which could make VGX-3100 the first non-surgical treatment for this condition in the country. For Inovio (NASDAQ: INO), a successful submission could trigger up to $20 million in milestone payments, followed by tiered royalties on future net sales in the Greater China region.
VGX-3100 is a DNA immunotherapy designed to elicit a T-cell response to clear persistent HPV infections, thereby promoting the regression of precancerous lesions. The goal is to provide patients with a therapeutic option that avoids or reduces the fertility-related risks, such as preterm birth and miscarriage, that can be associated with conventional surgical treatments like LEEP or conization.
According to the World Health Organization, cervical cancer was the fourth most common cancer in women globally in 2022, with around 660,000 new cases and 350,000 deaths. Currently, there are no therapeutic treatments approved in the United States for persistent HPV infection or the resulting cervical dysplasia.
The successful trial in China provides significant validation for Inovio's DNA medicine platform, which uses precisely designed DNA plasmids delivered via its proprietary CELLECTRA device. Investors will now watch for ApolloBio's formal submission to Chinese regulators and any updates on development for other HPV-related indications.
This article is for informational purposes only and does not constitute investment advice.
